Leaderboard

En | De
Sie sind hier: Urologie-Nephrologie » Tumoren/BPH 02. Dezember 2023
Suchen
medline.ch
Tumoren/BPH
Erweiterte Suche
Dermatologie
Endokrinologie
Ernährung
Gastroenterologie
Gynäkologie
Hämatologie
Infektiologie
Kardiovaskuläre Erkrankungen
Muskuloskelettale Erkrankungen
Neurologie
Onkologie
Ophthalmologie
ORL
Pädiatrie
Psychiatrie
Respirationstrakt
Sportmedizin
Urologie-Nephrologie
Entzündung-Infekt
Nephrolithiasis
Niereninsuffizienz
Sexualität
Tumoren/BPH
Anderes
Schrift: Schrift grösser Schrift kleiner

Rect Top
   Seite 1 von 8310  vorhergehende Seite nächste Seite
   
   Artikel 1 - 20 / 166194  
   
Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma.
J Immunother Cancer
Xu W, Lu J, Liu WR, Anwaier A, Wu Y, Tian X, Su JQ, Qu YY, Yang J, Zhang H, Ye D.
PMID: 38040418 [PubMed - in process]


Targeting tumor and bone microenvironment: Novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis.
Biochim Biophys Acta Rev Cancer
Li S, Kang Y, Zeng Y.
PMID: 38040267 [PubMed - as supplied by publisher]


Risk factors for prostate cancer in men with false-negative mpMRI: A retrospective single center cohort study of image quality scores and clinical parameters.
Eur J Radiol
Pausch AM, Ghafoor S, Kluckert J, Rupp NJ, Eberli D, Hötker AM.
PMID: 38039782 [PubMed - as supplied by publisher]


A case report of liver infiltration from a large renal cell carcinoma: Diagnostic and management enigma.
Int J Surg Case Rep
Choudhary D, Naik M, Vageesh BG, Agarwal A.
PMID: 38039569 [PubMed - as supplied by publisher]


Assessment of quantitative zonal parameters of prostate gland in discrimination of normal, benign, and malignant conditions: are these the more reliable parameters in the diagnosis of prostate cancer?
Eur Rev Med Pharmacol Sci
Karaca L, Özdemir ZM, Kahraman A, Çelik H, Kaya S.
PMID: 38039044 [PubMed - in process]


Racial and Ethnic Disparities in Use of Novel Hormonal Therapy Agents in Patients With Prostate Cancer.
JAMA Netw Open
Ma TM, Agarwal N, Mahal B, Barragan-Carrillo R, Spratt D, Rettig MB, Valle LF, Steinberg ML, Garraway I, Vapiwala N, Xiang M, Kishan AU.
PMID: 38039002 [PubMed - in process]


Recurrent prostate cancer: combined role for MRI and PSMA-PET in (68)Ga-PSMA-11 PET/MRI.
Eur Radiol
Jannusch K, Bruckmann NM, Morawitz J, Boschheidgen M, Quick HH, Herrmann K, Fendler WP, Umutlu L, Stuschke M, Hadaschik B, Antoch G, Schimmöller L, Kirchner J.
PMID: 38038758 [PubMed - as supplied by publisher]


Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
Cancer Med
Hannouneh ZA, Hijazi A, Alsaleem AA, Hami S, Kheyrbek N, Tanous F, Khaddour K, Abbas A, Alshehabi Z.
PMID: 38037752 [PubMed - as supplied by publisher]


A Notch signaling-related lncRNA signature for predicting prognosis and therapeutic response in clear cell renal cell carcinoma.
Sci Rep
Zhang L, Li Y, Cai B, Chen J, Zhao K, Li M, Lang J, Wang K, Pan S, Zhu K.
PMID: 38036719 [PubMed - in process]


Moving forward through consensus: a national Delphi approach to determine the top research priorities in prostate cancer in Uganda.
BMJ Open
Ssemata AS, Muhumuza R, Seeley J, Lombe DC, Mwamba M, Msadabwe S, Mwaka AD, Aggarwal A.
PMID: 38035740 [PubMed - in process]


Orexins and Prostate Cancer: State of the Art and Potential Experimental and Therapeutic Perspectives.
Cancer Genomics Proteomics
Costagliola A, Lombardi R, Liguori G, Morrione A, Giordano A.
PMID: 38035703 [PubMed - in process]


Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer.
Cancer Treat Rev
Efstathiou JA, Morgans AK, Bland CS, Shore ND.
PMID: 38035646 [PubMed - as supplied by publisher]


Redo nephron-sparing surgery in stage V pediatric renal tumors - A report from the SIOP/GPOH study group for renal tumors.
Eur J Surg Oncol
Fuchs J, Schunn MC, Schäfer JF, Ebinger M, Graf N, Furtwängler R, Warmann SW.
PMID: 38035461 [PubMed - as supplied by publisher]


OSM May Serve as a Biomarker of Poor Prognosis in Clear Cell Renal Cell Carcinoma and Promote Tumor Cell Invasion and Migration.
Int J Genomics
Wei S, Chen Y, Shi X, Zuo L, Zhang L.
PMID: 38034950 [PubMed]


Evaluation of proteolytic activity and serine proteases distribution in plasma from patients with bladder cancer.
Front Med (Lausanne)
Synelnyk T, Vovk T, Halenova T, Tytarenko V, Raksha N, Savchuk O, Falalyeyeva T, Ostapchenko L, Yakovlev P, Kozyk M, Thorley D, Strubchevska K.
PMID: 38034543 [PubMed]


Circadian Clock Dysregulation and Prostate Cancer: A Molecular and Clinical Overview.
Clin Med Insights Oncol
Kaakour D, Fortin B, Masri S, Rezazadeh A.
PMID: 38033743 [PubMed]


Association of obesity and different metabolic status with prognosis in patients with bladder cancer: a retrospective cohort study.
Ther Adv Urol
Dong Y, Cheng Y, Guo H, Sun J, Han J, Zhong F, Li Q, Wang D, Chen W, Fan X, Zhao J.
PMID: 38033708 [PubMed]


Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer - a narrative review.
Front Oncol
Szponar P, Petrasz P, Brze, Drewa T, Zorga P, Adamowicz J.
PMID: 38033494 [PubMed]


A Systems Biology Approach for Investigating Significant Biomarkers and Drug Targets Common Among Patients with Gonorrhea, Chlamydia, and Prostate Cancer: A Pilot Study.
Bioinform Biol Insights
Noman AA, Islam MK, Feroz T, Hossain MM, Shakil MSK.
PMID: 38033384 [PubMed]


Zero ischemia robotic partial nephrectomy: Oncological and functional outcomes of a multicenter study.
Turk J Med Sci
Ener K, Canda AE, Binbay M, Balbay MD, Atmaca AF.
PMID: 38031944 [PubMed - indexed for MEDLINE]


   
   Artikel 1 - 20 / 166194    Seite 1 von 8310  vorhergehende Seite nächste Seite

 
Rect Bottom
Adserver Footer
 

Benutzername

Passwort

 

 

Haben Sie Ihr Passwort vergessen?

 

Neu bei My Medline?

Melden Sie sich bei My Medline an!

 

Mehr über My Medline erfahren

mehr >>

  Zeitfenster  
   

Sky right 1